Aurinia Pharmaceuticals Inc


Canaccord Assumes a Speculative Buy on Aurinia Pharmaceuticals Inc (AUPH) Amid High Risk Factor for Biotech Drug Development

However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.

Aurinia Pharmaceuticals Inc (AUPH) Announces 2Q:17 Financial Results and Operational Update

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the second quarter ended June …

Aurinia Pharmaceuticals Inc (AUPH) Touts Remission Data from Lupus Nephritis Study

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) presented new duration of remission data from its global Phase IIB …

H.C. Wainwright Cuts Price Taget for Aurinia Pharmaceuticals Inc (AUPH) To Reflect Recent Share Dilution and Financial Overhang

Yesterday, drug maker Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the beginning of Phase 3 trial AURORA …

Aurinia Pharmaceuticals Inc (AUPH) Announces First Patient Dosed in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that the first patient has been dosed in AURORA, the …

Aurinia Pharmaceuticals Inc (AUPH): Betting on the Home Team

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is an all or nothing bet. The company’s future depends on …

Aurinia Pharmaceuticals Inc (AUPH) Announces Q1:17 Results

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the first quarter ended March …

Aurinia Pharmaceuticals, Inc. (AUPH) Scores Again With Voclosporin

Last week, on April 20, during the National Kidney Foundation 2017 Spring Clinical Meeting in …

Cantor Takes A Look At Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares rose 7% to $7.49 in Friday’s trading session, after the drug …